Cardiff Oncology Statistics

Total Valuation

FRA:XE7C has a market cap or net worth of EUR 110.82 million. The enterprise value is 61.26 million.

Market Cap	110.82M
Enterprise Value	61.26M

Important Dates

The last earnings date was Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	68.36M
Shares Outstanding	n/a
Shares Change (YoY)	+40.28%
Shares Change (QoQ)	+0.83%
Owned by Insiders (%)	2.42%
Owned by Institutions (%)	40.00%
Float	66.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	219.41
PB Ratio	2.87
P/TBV Ratio	2.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.57
EV / Sales	119.82
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.89

Financial Position

The company has a current ratio of 3.67, with a Debt / Equity ratio of 0.02.

Current Ratio	3.67
Quick Ratio	3.59
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -71.45% and return on invested capital (ROIC) is -46.83%.

Return on Equity (ROE)	-71.45%
Return on Assets (ROA)	-38.47%
Return on Invested Capital (ROIC)	-46.83%
Return on Capital Employed (ROCE)	-107.63%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	16,292
Profits Per Employee	-1.26M
Employee Count	31
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.60% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-55.60%
50-Day Moving Average	1.84
200-Day Moving Average	2.15
Relative Strength Index (RSI)	49.20
Average Volume (20 Days)	341

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	14.26

Income Statement

In the last 12 months, FRA:XE7C had revenue of EUR 505,058 and -39.07 million in losses. Loss per share was -0.58.

Revenue	505,058
Gross Profit	-1.52M
Operating Income	-41.70M
Pretax Income	-39.05M
Net Income	-39.07M
EBITDA	-41.39M
EBIT	-41.70M
Loss Per Share	-0.58

Full Income Statement

Balance Sheet

The company has 49.66 million in cash and 708,614 in debt, with a net cash position of 48.95 million.

Cash & Cash Equivalents	49.66M
Total Debt	708,614
Net Cash	48.95M
Net Cash Per Share	n/a
Equity (Book Value)	38.66M
Book Value Per Share	0.57
Working Capital	37.25M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -32.30 million and capital expenditures -37,475, giving a free cash flow of -32.34 million.

Operating Cash Flow	-32.30M
Capital Expenditures	-37,475
Free Cash Flow	-32.34M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-8,256.33%
Pretax Margin	-7,732.04%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:XE7C does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.28%
Shareholder Yield	-40.28%
Earnings Yield	-35.26%
FCF Yield	-29.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 20, 2019. It was a reverse split with a ratio of 0.1666666667.

Last Split Date	Feb 20, 2019
Split Type	Reverse
Split Ratio	0.1666666667

Scores

FRA:XE7C has an Altman Z-Score of -4.19 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.19
Piotroski F-Score	1